Walid A.M. Ganod

By Walid A.M. Ganod

This chapter sheds light on the cause and effect of chronic venous ulcers (CVUs) and the therapeutic procedures used to treat them. In the last two decades, many changes have occurred in the strategy of wound management through the development of adjunctive therapy that supports wound healing. Eventually, the latest development in platelet concentration technology produced platelet-rich fibrin (PRF). It was categorized as the second-generation platelet concentration family after platelet-rich plasma (PRP). Venous leg ulcers (VLUs) account for 70% of all leg ulcers and are estimated to affect 1% of the population; prevalence increases with age. The chronicity and refractory nature of venous ulcers have a great effect on the quality of life (QoL) and work productivity of patients, in addition to the expenditure of significant medical resources and efforts. Therefore, the goal of VLU management is to induce rapid healing without recurrence, which mainly helps to improve QoL. The first therapeutic procedure used in the treatment of VLU was compression therapy, in which the application of effective graduated compression decreased the overload in the venous system and venous reflux. Furthermore, it accelerated the capillary blood flow and decreased capillary fluid leakage, which alleviated limb edema.

Part of the book: Recent Advances in Wound Healing